Artrya Limited (AU:AYA)
ASX:AYA
AYA Stock Chart & Stats
AU$3.13
-AU$0.03(-4.17%)
At close: 4:00 PM EST
AU$3.13
-AU$0.03(-4.17%)
Day’s Range― - ―
52-Week RangeAU$0.56 - AU$5.24
Previous CloseN/A
Volume107.30K
Average Volume (3M)878.02K
Market Cap
AU$494.80M
Enterprise ValueAU$310.22M
Total Cash (Recent Filing)AU$76.67M
Total Debt (Recent Filing)AU$546.00K
Price to Earnings (P/E)―
Beta1.95
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.09
Shares Outstanding158,084,010
10 Day Avg. Volume1,092,517
30 Day Avg. Volume878,024
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)3.12
Price to Sales (P/S)2373.98
P/FCF Ratio-4.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$6.27Price Target Upside100.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$10.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageLow leverage provides financial flexibility while the company scales. With modest debt and an improving debt-to-equity ratio, Artrya faces lower near-term solvency risk and has capacity to raise incremental capital or sustain investment in product development without large fixed financing costs.
Early Commercial Traction / Revenue GrowthRecording first meaningful revenue in FY2025 and a large percentage increase from near-zero indicates initial product commercialization and early customer adoption. While absolute revenue is small, this step demonstrates a transition from R&D to market-facing operations, a necessary stage for scaling recurring revenue.
Scalable AI Software Business ModelA software-based diagnostic tool integrated into cardiology workflows suggests a scalable, low-marginal-cost model once adoption grows. Software and decision‑support positioning allow potential for recurring licensing, upgrades and broader deployment across hospitals, supporting margin expansion if clinical uptake accelerates.
Bears Say
High Cash Burn / Negative Operating Cash FlowSustained negative operating and free cash flow means the business is cash-consuming and will require external funding unless it quickly narrows losses. Ongoing cash burn limits runway, raises dilution risk for shareholders, and could constrain investment in commercialization and regulatory activities critical for long-term growth.
Persistently Loss-making With Weak MarginsThe company has not yet demonstrated operating leverage or sustainable margins. With revenue still minimal, fixed investment costs drive large negative margins; until scale is achieved and unit economics improve, profitability remains uncertain and the business may continue to consume capital.
Declining Equity And Negative Returns On CapitalDeclining equity and a sharply negative ROE reflect accumulated losses that erode shareholder value and indicate current capital deployment is not delivering positive returns. This weakens the firm’s financing profile and may necessitate recapitalization or dilution to support future growth.
Artrya Limited News
AYA FAQ
What was Artrya Limited’s price range in the past 12 months?
Artrya Limited lowest share price was AU$0.56 and its highest was AU$5.24 in the past 12 months.
What is Artrya Limited’s market cap?
Artrya Limited’s market cap is AU$494.80M.
When is Artrya Limited’s upcoming earnings report date?
Artrya Limited’s upcoming earnings report date is Aug 27, 2026 which is in 145 days.
How were Artrya Limited’s earnings last quarter?
Artrya Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.085 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.085.
Is Artrya Limited overvalued?
According to Wall Street analysts Artrya Limited’s price is currently Undervalued.
Does Artrya Limited pay dividends?
Artrya Limited does not currently pay dividends.
What is Artrya Limited’s EPS estimate?
Artrya Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Artrya Limited have?
Artrya Limited has 158,084,010 shares outstanding.
What happened to Artrya Limited’s price movement after its last earnings report?
Artrya Limited reported an EPS of -AU$0.085 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.166%.
Which hedge fund is a major shareholder of Artrya Limited?
Currently, no hedge funds are holding shares in AU:AYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Artrya Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$6.27 (100.32% Upside)
AU$6.27 (100.32% Upside)
Blogger Sentiment
Bullish
AU:AYA Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
781.57%
12-Months-Change
Fundamentals
Return on Equity
-35.63%
Trailing 12-Months
Asset Growth
453.47%
Trailing 12-Months
Company Description
Artrya Limited
Artrya Limited operates as a medical technology company that uses artificial intelligence (AI) to identify patients at risk of coronary artery disease. It offers Salix, a cloud-based software that uses its AI to automate the detection of coronary artery disease from coronary computed tomography angiography. The company was incorporated in 2018 and is based in West Perth, Australia.
AYA Stock 12 Month Forecast
Average Price Target
AU$6.27
▲(100.32% Upside)
Technical Analysis
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Singular Health Group Ltd
―
HitIQ Limited
―